RxDoctor Payments Data

Anthony Branz, MD

Family Medicine · Osburn, IDNPI 1700977170

Payments from drug & device makers

$443in general payments, 2019–2025

Across 26 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$172
  • AbbVie$59
  • Vanda Pharmaceuticals Inc.$54
  • Pfizer$43
  • Amgen$30
  • Lilly USA, LLC$29
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$172
AbbVie3$59
Vanda Pharmaceuticals Inc.2$54
Pfizer2$43
Amgen(2 entities)2$30
Lilly USA, LLC2$29
AstraZeneca2$25
GSK1$16
Abbott1$15

How this compares

$443 in reported general payments places this provider in the 60th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$138,589
Medicare patients
395
Services billed
6,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$111,541
OzempicSemaglutide114$107,492
TrulicityDulaglutide55$67,190
XifaxanRifaximin12$36,995
FarxigaDapagliflozin Propanediol28$25,593
JardianceEmpagliflozin29$22,252
XareltoRivaroxaban32$20,147
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$14,897
Tresiba Flextouch U-100Insulin Degludec27$11,728
Breo ElliptaFluticasone/Vilanterol28$10,969
Humalog Kwikpen U-100Insulin Lispro21$6,818
ZenpepLipase/Protease/Amylase18$6,324
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$6,196
SymbicortBudesonide/Formoterol Fumarate20$5,771
Atorvastatin Calcium675$4,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$111,541186 claims
Novo NordiskOzempic$172$107,492114 claims
Lilly USA, LLCTrulicity$29$67,19055 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$25$46,26262 claims
GSKBreo Ellipta, Incruse Ellipta$16$15,14740 claims
AbbVieSynthroid$59$2,76149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 803 family medicine providers in Idaho.

Other family medicine in Osburn

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →